Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an
Celine Miyazaki1, Nagano Katsumasa2, Kuan Chih Huang3
1Health Economics Department, Janssen Pharmaceutical K.K., Tokyo, Japan.
Insights
Biologics reduce healthcare resource use in Crohn's Disease (CD) patients in Japan. While initial costs rise, long-term use may decrease overall economic burden.
Area of Science:
- Gastroenterology
- Health Economics
- Pharmacoeconomics
Background:
- Crohn's Disease (CD) management in Japan often involves biologics for moderate to severe cases.
- Updated economic data post-ustekinumab approval for CD in Japan is limited.
- CD imposes significant direct healthcare costs on the Japanese healthcare system.
Purpose of the Study:
- To evaluate healthcare resource utilization (HRU) and direct costs associated with biologics for CD in Japan.
- To assess changes in HRU and costs from a payer's perspective.
- To provide updated economic insights following the introduction of newer biologics.
Main Methods:
- Retrospective analysis of Japanese claims data from 2010-2018.
- Identification of patients with Crohn's Disease (CD).
- Evaluation of HRU and costs 12 months pre- and post-biologic initiation, with follow-up up to 36 months.
Main Results:
- Biologic initiation correlated with reduced inpatient stays, length of stay, and outpatient visits.
- Associated direct costs decreased post-biologic initiation, though pharmacy costs and total costs initially increased.
- HRU and costs showed a decreasing trend up to 24 months, with a subsequent rise after 36 months.
Conclusions:
- Biologics appear to reduce the clinical burden of Crohn's Disease (CD).
- A slight increase in the economic burden was observed with biologic use.
- Further evaluation including indirect costs is necessary for a comprehensive economic assessment.
Abstract:
Biologics are recommended in Japan to treat moderate to severe Crohn's Disease (CD). Although CD is associated with high direct costs in Japan, updated information after ustekinumab's approval is unavailable. We aimed to evaluate the healthcare resource utilization (HRU) and associated direct costs from the payer's perspective in Japan. Claims data (2010-2018) were retrospectively analyzed to identify patients with CD. HRU and associated costs were evaluated for 12 months before and after biologic initiation and followed-up till 36 months post-initiation. Outcomes were reported using descriptive statistics. Among the included patients (n = 3,496), 1,783 were on biologics and 1,713 were on non-biologics. Mean (SD) age was 36.4 (13.2) years and patients were predominantly male (76.1%). Patients aged 18-39 years were affected with CD the most (55.3%). Biologic initiation was associated with a reduction in inpatient stay, length of stay, outpatient visits, and associated costs; and an increase in pharmacy costs and total costs after 12 months. Extended follow-up showed a decreasing trend in HRU and costs till 24 months but an increase after 36 months. These findings demonstrated reduction in clinical burden and slight increase in economic burden with biologics. However, indirect costs also need to be evaluated.
More Related Videos
08:27Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...